Rifampicin or rifampin

This classification denotes a rna polymerase inhibitor and antitubercular agent with the molecular formula C43H58N4O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VJT6J7R4TR, chemically known as 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(n-(4-methyl-1-piperazinyl)formimidoyl)-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2h)-dione 21-acetate but generally known as rifampicin, which bears US NIH Compound Identifier 5381226. European Medicines Agency schedules Rifampicin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10309MIG. The term RIFAMPICIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). World Health Organization schedules rifampicin in its Anatomical Therapeutic Chemical (ATC) Classification. RIFAMPICIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Rifampicinn or rifampin bears US NLM NCI C811. SMILES: O(C1C(C(O)C(C(O)C(C)C=CC=C(C(=O)NC2=C(O)C3C(C4C(=O)C(OC=CC(OC)C1C)(OC4C(C3O)C)C)C(=O)/C2=C/NN1CCN(CC1)C)C)C)C)C(=O)C.